8-K: Femasys Inc. Announces 1-for-20 Reverse Stock Split

Femasys Inc. will implement a 1-for-20 reverse stock split, effective June 5, 2026, with trading on a split-adjusted basis commencing June 8, 2026.

Summary

• Femasys Inc. announced a 1-for-20 reverse stock split of its common stock.
• The reverse stock split will become effective at 4:30 p.m. Eastern Time on June 5, 2026.
• The company's common stock will commence trading on a split-adjusted basis at the market open on June 8, 2026.
• The stock will continue to trade under the existing symbol FEMY.
• A new CUSIP number for the common stock will be 31447E 204.
• Each 20 pre-split shares will be converted into one post-split share.
• Fractional shares will not be issued; instead, they will be rounded up to the next whole share at the DTC participant level.
• Shareholders of record will receive information from the transfer agent, Broadridge Investor Communication Solutions, Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, as a reverse stock split is often a sign of past underperformance and an attempt to avoid delisting rather than a fundamental business improvement.

Positives

• The reverse stock split is intended to increase the market price of the company's common stock.
• The company aims to meet the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC.

Negatives

• The reverse stock split does not change the total number of outstanding shares, only the per-share price and number of shares outstanding.
• No fractional shares will be issued, which could lead to minor adjustments for some shareholders.

Risks

• The ability to obtain regulatory approvals for the FemBloc product candidate.
• The ability to develop and advance the FemBloc product candidate and successfully enroll and complete clinical trials.
• The ability of clinical trials to demonstrate safety and effectiveness of product candidates.
• Estimates regarding the total addressable market for products and product candidates.
• The ability to commercialize products and product candidates.
• The ability to establish, maintain, grow, or increase sales and revenues.
• The effect of delays in commercializing products, including FemaSeed.
• The company's business model and strategic plans for its products, technologies, and business, including implementation.

Future Outlook

The filing contains forward-looking statements regarding the company's ability to obtain regulatory approvals, develop and commercialize product candidates like FemBloc and FemaSeed, enroll and complete clinical trials, and achieve sales and revenue growth. These statements are subject to substantial risks and uncertainties that could cause actual results to differ materially.

Management Comments

• The company undertakes no duty to update forward-looking statements except as required under applicable law.

Industry Context

StockSavvy.ai notes that reverse stock splits are often undertaken by companies to increase their stock price to meet exchange listing requirements, such as the minimum bid price on Nasdaq. This action is typically a response to a sustained period of low share price.

Stakeholder Impact

• Shareholders will hold fewer shares, but the total value of their holdings is intended to remain the same immediately after the split, subject to market fluctuations.
• Shareholders may experience a change in their per-share ownership percentage if fractional shares are rounded up.
• The Nasdaq Stock Market LLC's listing requirements will be addressed by the increased share price.

Next Steps

• Common stock to trade on a split-adjusted basis starting June 8, 2026.
• Shareholders to receive information regarding their post-split share ownership from Broadridge.

Key Dates

Recommendation

A reverse stock split is primarily a cosmetic change to meet listing requirements and does not inherently improve the company's underlying business performance or prospects. Investors should continue to monitor the company's progress on its product development and commercialization efforts, as detailed in the risk factors, rather than relying on the stock split itself for future gains.

Keywords

reverse stock split, Femasys Inc., FEMY, Nasdaq, common stock, stock adjustment, corporate action, shareholder information